Project PEER

The overarching goal of Project PEER is to understand the lung cancer patient experience, irrespective of diagnosis (stage/histology), outside of the clinical trial setting.

Lung cancer continues to be the number one cancer killer in the United States and worldwide. In the last few years, science has progressed at an unprecedented rate as new categories of therapies have become available (including immunotherapies and targeted therapies with companion diagnostics) and the application of existing therapies has expanded. Yet, the prescribing preferences for different first-line and subsequent-line treatments are currently not known. Furthermore, reasons for treatment discontinuation (adverse events, progression, mechanisms of resistance, etc) are not well documented beyond a clinical trial context. Likewise, how patients experience their disease in terms of symptoms, impacts, outcomes, and quality of life (QoL) throughout their disease progression is unclear.

The main objectives of Project PEER are as follows:

  1. Catalog the diagnostic and treatment journey of patients
  2. Collect exploratory patient-experience data in different domains (financial impact/data from patient-reported outcomes [PRO] instruments)
  3. Test the hypothesis that different classes of therapies (chemotherapy, immunotherapy, targeted therapy, surgery, radiation) and the exact point of a patient’s treatment journey affect patient experience and compare findings from study with currently existing clinical trial data

Project PEER aims to catalog the variables described above to answer the following questions:

  1. How does treatment sequencing affect the quality of life of lung cancer patients?
  2. Do patients on clinical trials fare better than those not on trials?
  3. Does age at diagnosis affect the treatment journey of lung cancer patients?

Project PEER is an international study and open to any participant who is able to read and respond to questions in English.

Interested in participating in Project PEER? Please email us at [email protected].

 

Results to Date

None to disclose